Schering Plough Reports Preladenant Meets Primary Endpoint In Phase II Dose-Finding Trial For Parkinson’s Disease

Schering-Plough Corporation (NYSE: SGP) reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients suffering from moderate to severe Parkinson’s disease experiencing motor fluctuations and abnormal involuntary movements (dyskinesias). The trial results were presented at the company’s 2008 R&D Update meeting being hosted for analysts and portfolio managers at company headquarters.

More: continued here

Filed under: Clinical Trials on November 25th, 2008